Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGXSWX:SDZ +2.43%11 EV-to-EBITDA is 20.17 as of Jul. 22, 2026, which is 18% below its 10-year median of 24.52. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 741 Drug Manufacturers companies, Sandoz Group AG ranks worse than 67.34% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sandoz Group AG's enterprise value is CHF31,987 Mil.
Sandoz Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1,586 Mil. Therefore, Sandoz Group AG's EV-to-EBITDA for today is 20.17.
The historical rank and industry rank for Sandoz Group AG's EV-to-EBITDA or its related term are showing as below:
XSWX:SDZ'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.83 Med: 24.52 Max: 43.39
Current: 20.17
During the past 4 years, the highest EV-to-EBITDA of Sandoz Group AG was 43.39. The lowest was 6.83. And the median was 24.52.
XSWX:SDZ's EV-to-EBITDA is ranked worse than 67.34% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.24
vs XSWX:SDZ: 20.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Sandoz Group AG (XSWX:SDZ) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sandoz Group AG's PE Ratio (TTM) for today is calculated as:
Sandoz Group AG's share price for today is CHF66.54.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sandoz Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1.679.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sandoz Group AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SDZ vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's EV-to-EBITDA falls into.
Sandoz Group AG's current Enterprise Value is CHF31,987 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sandoz Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1,586 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (XSWX:SDZ) has a EV-to-EBITDA of 20.17 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sandoz Group AG. This is 18% below median its historical median of 24.52. Over the past decade, Sandoz Group AG's EV-to-EBITDA has ranged from 6.83 to 43.39. According to the industry distribution chart, Sandoz Group AG ranks #499 out of 741 companies in the Drug Manufacturers industry, placing it in the top 67.3%.
Is Sandoz Group AG's EV-to-EBITDA too high?
Sandoz Group AG's current EV-to-EBITDA of 20.17 is 18% below median its 10-year median of 24.52. Over the past 10 years, this metric has ranged from a low of 6.83 to a high of 43.39. The Drug Manufacturers industry median EV-to-EBITDA is 13.24. Sandoz Group AG's value of 20.17 is 52.3% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #499 out of 741 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #499 out of 741 companies for EV-to-EBITDA. This places Sandoz Group AG in the lower half of its industry. The industry median EV-to-EBITDA is 13.24. Sandoz Group AG's value of 20.17 is 52.3% above this benchmark. Historically, Sandoz Group AG's own EV-to-EBITDA has ranged from 6.83 to 43.39 over the past decade. While the company's 10-year median is 24.52 vs. the industry median of 13.24, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.24, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current EV-to-EBITDA of 20.17 is 52.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sandoz Group AG. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current EV-to-EBITDA is 20.17, which is 18% below median its own 10-year median of 24.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current EV-to-EBITDA of 20.17. The current EV-to-EBITDA is 20.17, which is 18% below median its 10-year median of 24.52 and 52.3% above the Drug Manufacturers industry median of 13.24. Sandoz Group AG's overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current EV-to-EBITDA is 20.17 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score
Get the complete analysis for XSWX:SDZ
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SDZ has been successfully added to your 
